BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19386079)

  • 21. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes.
    Barsoum RS; Morsey AA; Iskander IR; Morgan MM; Fayad TM; Atalla NT; Wafik H; Grace RA; Adel N; Khalil SS
    Exp Clin Transplant; 2007 Dec; 5(2):649-57. PubMed ID: 18194116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study.
    Nickerson P; Jeffery J; Gough J; Grimm P; McKenna R; Birk P; Rush D
    J Am Soc Nephrol; 1999 Aug; 10(8):1801-5. PubMed ID: 10446949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression.
    Sakai K; Miyagi Y; Hasegawa T; Itabashi Y; Muramatsu M; Sugiyama K; Kawamura T; Arai K; Aikawa A; Ohara T; Mizuiri S; Hasegawa A
    Transplant Proc; 2005 May; 37(4):1757-9. PubMed ID: 15919455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
    Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation.
    Dandel M; Jasaityte R; Lehmkuhl H; Knosalla C; Hetzer R
    Transplant Proc; 2009; 41(6):2585-8. PubMed ID: 19715979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
    Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
    Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M; Banasik M; Patrzałek D; Klinger M
    Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: a single center experience.
    Masutani K; Kitada H; Tsuchimoto A; Yamada S; Noguchi H; Tsuruya K; Tanaka M; Iida M
    Clin Exp Nephrol; 2011 Apr; 15(2):264-8. PubMed ID: 21170758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
    Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
    Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
    Attallah N; Goggins M; Nori U; Abouljoud M; Zasuwa G; Venkat KK; Parasuraman R
    Transplant Proc; 2005 Jun; 37(5):2060-2. PubMed ID: 15964338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.